Drugs / Panblok H7
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03038776 | Jan → Nov 2017 | avian influenza | Vaxine Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05608005 | Nov 2022 → Feb 2023 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03283319 | Sep → Dec 2017 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PanBlok H7 | “PanBlok H7 is a pandemic influenza vaccine produced by PSC in the same way as Flublok but it is directed against H7 rather than seasonal influenza virus strains.” NCT03038776 ↗ |
| Modality | Vaccine | “0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.” NCT03283319 ↗ |
| Route | Intramuscular | “Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03” NCT03283319 ↗ |